{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:32:38Z","timestamp":1786984358094,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Creighton University School of Pharmacy & Allied Health Professions Wareham Research"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.antiviral.2019.04.007","type":"journal-article","created":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T10:26:08Z","timestamp":1555151168000},"page":"83-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["A potential long-acting bictegravir loaded nano-drug delivery system for HIV-1 infection: A proof-of-concept study"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0047-4305","authenticated-orcid":false,"given":"Subhra","family":"Mandal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavan Kumar","family":"Prathipati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Belshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7923-3939","authenticated-orcid":false,"given":"Christopher J.","family":"Destache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.04.007_bib1","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1007\/s11051-014-2527-7","article-title":"Overview of nano-drugs characteristics for clinical application: the journey from the entry to the exit point","volume":"16","author":"Bose","year":"2014","journal-title":"J. Nanoparticle Res."},{"key":"10.1016\/j.antiviral.2019.04.007_bib2","doi-asserted-by":"crossref","first-page":"35211","DOI":"10.1074\/jbc.M301257200","article-title":"Active cAMP-dependent protein kinase incorporated within highly purified HIV-1 particles is required for viral infectivity and interacts with viral capsid protein","volume":"278","author":"Cartier","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2019.04.007_bib3","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1128\/AAC.00450-16","article-title":"Topical tenofovir disoproxil fumarate nanoparticles prevent HIV-1 vaginal transmission in a humanized mouse model","volume":"60","author":"Destache","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.04.007_bib4","series-title":"Bictegravir","author":"Drugbank","year":"2016"},{"key":"10.1016\/j.antiviral.2019.04.007_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/aid.2014.0210","article-title":"Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates","volume":"31","author":"Freeling","year":"2015","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.antiviral.2019.04.007_bib6","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2019.04.007_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/QAI.0000000000001306","article-title":"Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-Infected adults","volume":"75","author":"Gallant","year":"2017","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2019.04.007_bib8","series-title":"Food and Drug Administration","article-title":"Center for drug evaluation and research. Application number- 210251Orig1s000. Trade Name: BIKTARVY tablets","author":"Gilead Sciences","year":"2018"},{"key":"10.1016\/j.antiviral.2019.04.007_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01695-17","article-title":"Antiviral activity of bictegravir and cabotegravir against integrase inhibitor-resistant SIVmac239 and HIV-1","volume":"61","author":"Hassounah","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.04.007_bib10","series-title":"TZM-bl Cells","author":"Kappes","year":"2018"},{"key":"10.1016\/j.antiviral.2019.04.007_bib11","series-title":"TZM-bl Cells Data Sheet","author":"Kappes","year":"2015"},{"key":"10.1016\/j.antiviral.2019.04.007_bib12","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers"},{"key":"10.1016\/j.antiviral.2019.04.007_bib13","series-title":"HIV-1 NL4-3 Infectious Molecular Clone (pNL4-3)","author":"Malcolm","year":"2017"},{"key":"10.1016\/j.antiviral.2019.04.007_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01475-16","article-title":"An enhanced emtricitabine-loaded long-acting nanoformulation for prevention or treatment of HIV infection","volume":"61","author":"Mandal","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.04.007_bib15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.06.005","article-title":"Long-acting parenteral combination antiretroviral loaded nano-drug delivery system to treat chronic HIV-1 infection: a humanized mouse model study","volume":"156","author":"Mandal","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.04.007_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/polym9090423","article-title":"Cellulose acetate phthalate and antiretroviral nanoparticle fabrications for HIV pre-exposure prophylaxis","volume":"9","author":"Mandal","year":"2017","journal-title":"Polymers"},{"key":"10.1016\/j.antiviral.2019.04.007_bib17","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/QAD.0000000000001349","article-title":"Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission","volume":"31","author":"Mandal","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2019.04.007_bib18","first-page":"e4379","article-title":"Development and validation of LC\u2013MS\/MS method for quantification of bictegravir in human plasma and its application to an intracellular uptake study","volume":"0","author":"Prathipati","year":"2018","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.antiviral.2019.04.007_bib19","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1007\/s11095-017-2255-7","article-title":"Pharmacokinetic and tissue distribution profile of long acting tenofovir alafenamide and elvitegravir loaded nanoparticles in humanized mice model","volume":"34","author":"Prathipati","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.antiviral.2019.04.007_bib20","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3018(17)30016-4","article-title":"Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial","volume":"4","author":"Sax","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.antiviral.2019.04.007_bib21","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2019.04.007_bib22","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/cpr.12192","article-title":"Independent effect of polymeric nanoparticle zeta potential\/surface charge, on their cytotoxicity and affinity to cells","volume":"48","author":"Shao","year":"2015","journal-title":"Cell Prolif"},{"key":"10.1016\/j.antiviral.2019.04.007_bib23","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1089\/aid.2012.0301","article-title":"Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment","volume":"29","author":"Shibata","year":"2013","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.antiviral.2019.04.007_bib24","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/COH.0000000000000002","article-title":"Long-acting injectable antiretrovirals for HIV treatment and prevention","volume":"8","author":"Spreen","year":"2013","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.antiviral.2019.04.007_bib25","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.04.007_bib26","first-page":"247","article-title":"Recent advances in lymphatic targeted drug delivery system for tumor metastasis","volume":"11","author":"Zhang","year":"2014","journal-title":"Cancer Biol. Med."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218306351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218306351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:28:28Z","timestamp":1759062508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218306351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":26,"alternative-id":["S0166354218306351"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.04.007","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A potential long-acting bictegravir loaded nano-drug delivery system for HIV-1 infection: A proof-of-concept study","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}